MedPath

Evolution of PET Fixation With FDG at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis

Not Applicable
Not yet recruiting
Conditions
Prosthetic Valve Endocarditis
Registration Number
NCT05989152
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

In patients with prosthetic valve endocarditis (PVE) and pathological valvular FDG uptake on the initial FDG-PET and not referred to valve replacement at the acute phase, the study will assess whether FDG-PET is able to identify those at increased risk of PVE relapse.

Detailed Description

In patients medically treated for prosthetic valve infection (PVE), identification of persistent infection or of cure could be very useful to 1/ patients referral to high-risk surgery, 2/ initiation of suppressive antibiotic therapy, or 3/ simplify the follow-up in other patients. The hypothesis is that FDG-PET could thus identify patients at increased risk of recurrence in case of persistent pathological uptake In patients with prosthetic endocarditis and pathological valvular FDG uptake on the initial FDG-PET and not referred to valve replacement at the acute phase, the main objective is to estimate the proportion of those still showing pathological valvular FDG uptake after curative antibiotic treatment. The secondary objectives are 1/ to quantitatively compare the valvular FDG-PET uptake for each individual before and after treatment; 2/ to determine the proportion of those in whom extracardiac foci persist at the end of treatment ; 3/ to evaluate the association between valvular FDG uptake on PET at the end of treatment and PVE relapse at 6 months; 4/ to evaluate the diagnostic performance of an automatic analysis by artificial intelligence of FDG uptake before and after treatment to predict PVE relapse at 6 months.

This is a single-center prospective cohort study. The population is composed of 50 adults with definite PVE according to the ESC 2015 classification, not operated in the acute phase and with pathological FDG-PET at the beginning of curative antibiotic treatment.

A change in practices regarding the duration of antibiotic therapy and the use of valve replacement surgery and its potential complications would benefit patients and reduce the overall cost related to valve prosthesis infection to the healthcare system."

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Presence of pathological uptake on the prosthetic valve on FDG-PETat inclusion

Presence of pathological uptake on the prosthetic valve on FDG-PET performed after the recommended duration of curative antibiotic treatment

Secondary Outcome Measures
NameTimeMethod
Presence of the intensity of extracardiac uptake on the FDG-PET at the end of curative antibiotic treatment in patients presenting with pathological extracardiac uptake on the initial FDG-PETat inclusion

by comparing the intensity of extracardiac uptake between FDG-PET initial and at the end of curative antibiotic treatment

Relapse of endocarditis defined by the same location and the same microorganism within 6 months6 month
Evolution of the FDG uptake intensity on the prosthetic valve by FDG-PETat inclusion

by comparing the FDG uptake intensity on the prosthetic valve between initial and at the end of curative antibiotic treatment FDG-PET

Therapeutic impact of end-of-treatment PET-FDG measured by stopping or continuing antibiotic treatment6 month

measured by stopping or continuing antibiotic treatment

Diagnostic performance of AI to predict relapse of endocarditis defined by the same location and the same microorganism within 6 months6 month

classification

Evolution of the intensity of extracardiac uptake on the FDG-PET at the end of curative antibiotic treatment in patients presenting with pathological extracardiac uptake on the initial FDG-PETat inclusion

by comparing the intensity of extracardiac uptake between FDG-PET initial and at the end of curative antibiotic treatment

Trial Locations

Locations (1)

Hôpital Bichat-Claude Bernard

🇫🇷

Paris, France

Hôpital Bichat-Claude Bernard
🇫🇷Paris, France
François Rouzet, MD, PHD
Contact
01.40.25.64.11
francois.rouzet@aphp.fr
Xavier Duval, MD, PHD
Contact
xavier.duval@aphp.fr
© Copyright 2025. All Rights Reserved by MedPath